Two randomized controlled trials of SB742457 in mild-to-moderate Alzheimer's disease.

ABSTRACT:

Background

Two previous studies of SB742457, a 5-hydroxytryptamine (5-HT₆) receptor antagonist, suggested the efficacy of improvements in cognition and global outcome in Alzheimer's disease (AD).

Methods

Two randomized, placebo-controlled trials investigated SB742457 15 and 35 mg daily in subjects with mild-to-moderate AD (Mini-Mental Health State Examination [MMSE] 10-26). Study 1 (n = 576) investigated SB742457 and donepezil (5-10 mg daily) as monotherapy for 6 months. Study 2 (n = 684) investigated SB742457 in subjects who were maintained on donepezil. Coprimary endpoints at 24 weeks assessed cognition (AD Assessment Scale-Cognitive Subscale [ADAS-Cog]) and global outcome (Study 1: Clinician Interview-Based Impression of Change Plus Caregiver Input [CIBIC+]; St

SUBMITTER: Maher-Edwards G 

PROVIDER: S-EPMC5974972 | biostudies-literature | 2015 Jun

REPOSITORIES: biostudies-literature